TD Private Client Wealth LLC Sells 1,933 Shares of Humana Inc. $HUM

Key Points

• TD Private Client Wealth LLC reduced its holdings in Humana Inc. by 91.0%, selling 1,933 shares in the 2nd quarter, leaving it with only 192 shares valued at $47,000.
• Several institutional investors, including Vanguard Group and Dodge & Cox, increased their stakes in Humana during the first quarter, indicating interest from major investors.
• Humana announced a quarterly dividend of $0.885, representing a 1.4% yield, with the ex-dividend date set for September 26th.

TD Private Client Wealth LLC decreased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 91.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 192 shares of the insurance provider's stock after selling 1,933 shares during the quarter. TD Private Client Wealth LLC's holdings in Humana were worth $47,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after acquiring an additional 1,143,662 shares in the last quarter. Dodge & Cox lifted its position in Humana by 5.5% in the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock valued at $2,845,830,000 after acquiring an additional 557,175 shares in the last quarter. Pzena Investment Management LLC lifted its position in Humana by 6.1% in the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock valued at $1,013,133,000 after acquiring an additional 219,541 shares in the last quarter. Davis Selected Advisers lifted its position in Humana by 3.3% in the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock valued at $616,873,000 after acquiring an additional 74,434 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC lifted its position in Humana by 1.6% in the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider's stock valued at $327,293,000 after acquiring an additional 19,613 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on HUM. Robert W. Baird dropped their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Bank of America lifted their target price on shares of Humana from $285.00 to $312.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. Morgan Stanley dropped their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Wall Street Zen cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Barclays lifted their target price on shares of Humana from $275.00 to $315.00 and gave the stock an "equal weight" rating in a research report on Friday, September 5th. Seven analysts have rated the stock with a Buy rating and seventeen have issued a Hold rating to the company's stock. According to data from MarketBeat, Humana presently has a consensus rating of "Hold" and an average target price of $289.50.

Humana Trading Up 0.0%

Shares of HUM stock opened at $255.06 on Tuesday. The company has a 50 day moving average of $272.54 and a 200-day moving average of $257.43. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $324.38. The firm has a market cap of $30.68 billion, a P/E ratio of 19.57, a PEG ratio of 1.50 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter in the prior year, the firm posted $6.96 earnings per share. The firm's quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, September 26th. Humana's payout ratio is currently 27.17%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.